Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 6/2021

01-06-2021 | Obesity | Brief Communication

Roux-en-Y Gastric Bypass Downregulates Angiotensin-Converting Enzyme 2 (ACE2) Gene Expression in Subcutaneous White Adipose Tissue: A Putative Protective Mechanism Against Severe COVID-19

Authors: Leonardo Kristem, Mariana Recamonde-Mendoza, Giuliano C. Cigerza, Jad Khoraki, Guilherme M. Campos, Guilherme S. Mazzini

Published in: Obesity Surgery | Issue 6/2021

Login to get access

Abstract

The angiotensin-converting enzyme 2 (ACE2) is the receptor for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is highly expressed in adipose tissue, possibly associated with progression to severe coronavirus disease 2019 (COVID-19) in obese subjects. We searched the Gene Expression Omnibus (GEO) and reanalyzed the GSE59034 containing microarray data from subcutaneous white adipose tissue (sWAT) biopsies from 16 women before and 2 years after RYGB, and 16 controls matched by sex, age, and BMI. After RYGB, there was a significant decrease in sWAT ACE2 gene expression (logFC=-0.4175, P=0.0015). Interestingly, after RYGB the sWAT ACE2 gene expression was significantly lower than in non-obese matched controls (LogFC=-0.32875, P=0.0014). Our data adds to the well-known benefits of RYGB, a potential protective mechanism against COVID-19.

Graphical Abstract

Literature
1.
Popkin B, Du S, Green W, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21(11):e13128.CrossRefPubMed
2.
Sattar N, McInnes I, McMurray J. Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation. 2020;142(1):4–6.CrossRefPubMed
3.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.CrossRefPubMedPubMedCentral
4.
Garvin M, Alvarez C, Miller J, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020;9:e59177.CrossRefPubMedPubMedCentral
5.
Sanchis-Gomar F, Lavie C, Mehra M, et al. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. Mayo Clin Proc. 2020;95(7):1445–53.CrossRefPubMed
6.
Arterburn D, Telem D, Kushner R, et al. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879–87.CrossRefPubMed
7.
Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991–5.PubMed
8.
Petrus P, Mejhert N, Corrales P, et al. Transforming growth factor-β3 regulates adipocyte number in subcutaneous white adipose tissue. Cell Rep. 2018;25(3):551–560.e5.CrossRefPubMed
9.
10.
Iannelli A, Bouam S, Schneck A, et al. The impact of previous history of bariatric surgery on outcome of Covid-19: a nationwide medico-administrative French study. Obes Surg. 2020;18:1–9.
Metadata
Title
Roux-en-Y Gastric Bypass Downregulates Angiotensin-Converting Enzyme 2 (ACE2) Gene Expression in Subcutaneous White Adipose Tissue: A Putative Protective Mechanism Against Severe COVID-19
Authors
Leonardo Kristem
Mariana Recamonde-Mendoza
Giuliano C. Cigerza
Jad Khoraki
Guilherme M. Campos
Guilherme S. Mazzini
Publication date
01-06-2021
Publisher
Springer US
Published in
Obesity Surgery / Issue 6/2021
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-021-05271-7

Other articles of this Issue 6/2021

Obesity Surgery 6/2021 Go to the issue

Letter to the Editor

Dignity and Respect: People-First Language with Regard to Obesity

Original Contributions

Early Effects of Laparoscopic Sleeve Gastrectomy and Laparoscopic One-Anastomosis Gastric Bypass on Portal Venous Flow: a Prospective Cohort Study

Multimedia Article

Laparoscopic Conversion of Sleeve Gastrectomy to One Anastomosis Gastric Bypass in a Hostile Abdomen

Original Contributions

Sociodemographic Factors Associated with Loss to Follow-Up After Bariatric Surgery

Original Contributions

Comparative Effectiveness of Roux-en-Y Gastric Bypass vs. One Anastomosis Gastric Bypass on Kidney Function

Original Contributions

Analysis of National Bariatric Surgery Related Clinical Incidents: Lessons Learned and a Proposed Safety Checklist for Bariatric Surgery